<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028582</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-154-309</org_study_id>
    <nct_id>NCT05028582</nct_id>
  </id_info>
  <brief_title>Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)</brief_title>
  <acronym>ARRECTOR</acronym>
  <official_title>A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily&#xD;
      for 8 weeks by subjects with scalp and body psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or&#xD;
      vehicle foam is applied once daily for 8 weeks to subjects with scalp and body psoriasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scalp Investigator Global Assessment (S-IGA) Score Change</measure>
    <time_frame>8 weeks</time_frame>
    <description>S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Investigator Global Assessment (B-IGA) Score Change</measure>
    <time_frame>8 weeks</time_frame>
    <description>B-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In subjects with a Baseline SI-NRS (Scalp Itch-Numeric Rating Score) pruritus score of ≥ 4, SI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline.</measure>
    <time_frame>Week 8</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with a Baseline SI-NRS (Scalp Itch-Numeric Rating Score) pruritus score of ≥ 4, SI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline.</measure>
    <time_frame>Week 4</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with a Baseline SI-NRS (Scalp Itch-Numeric Rating Score) pruritus score of ≥ 4, SI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline.</measure>
    <time_frame>Week 2</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)</measure>
    <time_frame>Week 1</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)</measure>
    <time_frame>72 Hours</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (CFB) SI-NRS (Scalp Itch-Numeric Rating Score)</measure>
    <time_frame>Day 1</time_frame>
    <description>SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with a Baseline WI-NRS (Worst Itch-Numeric Rating Score) pruritus score of ≥ 4, WI-NRS Success, defined as achievement of a ≥ 4-point improvement from Baseline</measure>
    <time_frame>Week 8</time_frame>
    <description>WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI-75 (Psoriasis Area and Severity Index-75)</measure>
    <time_frame>Week 8</time_frame>
    <description>A PASI score is a tool used to measure the severity and extent of psoriasis. Psoriasis Area and Severity Index-75; subjects who achieve a 75% reduction in PASI from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (CFB) in total PSD (Psoriasis Symptoms Diary) score</measure>
    <time_frame>Week 8</time_frame>
    <description>The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (CFB) in total PSD (Psoriasis Symptoms Diary) score</measure>
    <time_frame>Week 4</time_frame>
    <description>The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (CFB) in total PSD (Psoriasis Symptoms Diary) score</measure>
    <time_frame>Week 2</time_frame>
    <description>The PSD is a 16-item assessment that measures psoriasis symptoms and impact on functional health. Symptom items assess the severity and bother of psoriasis-related itching, stinging, burning, pain, scaling, and skin color.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSSI-75 (Psoriasis Scalp Severity Index)</measure>
    <time_frame>Week 8</time_frame>
    <description>The PSSI is used for the measurement of severity of psoriasis. PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI-75 indicates at least a 75% improvement in the PSSI score from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-IGA (Scalp Investigator Global Assessment) of 'Clear' at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The S-IGA is a global assessment scale that has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SI-IGA (Scalp Investigator Global Assessment)</measure>
    <time_frame>Week 4</time_frame>
    <description>S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 4. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (CFB) in PASI (Psoriasis Scalp Severity Index)</measure>
    <time_frame>Week 2</time_frame>
    <description>A PASI score is a tool used to measure the severity and extent of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-IGA (Scalp-Investigator Global Assessment) Success</measure>
    <time_frame>Week 2</time_frame>
    <description>S-IGA Success, defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement at Week 2. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Scalp Psoriasis</condition>
  <arm_group>
    <arm_group_label>ARQ-154 Foam 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARQ-154 Foam 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-154 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ARQ-154 Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-154 Foam 0.3%</intervention_name>
    <description>ARQ-154 Foam 0.3%</description>
    <arm_group_label>ARQ-154 Foam 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-154 Vehicle</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>ARQ-154 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For adult subjects: Participants legally competent to read, write, and sign and give&#xD;
             informed consent. For adolescent subjects: Informed consent of a parent(s) or legal&#xD;
             guardian, and assent by the subjects, as required by local laws.&#xD;
&#xD;
          -  Males and females ages 12 years and older (inclusive) at the time of consent or&#xD;
             assent.&#xD;
&#xD;
          -  Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA)&#xD;
             severity of at least Moderate ('3') at Baseline.&#xD;
&#xD;
          -  Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline.&#xD;
&#xD;
          -  A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline.&#xD;
&#xD;
          -  An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline.&#xD;
&#xD;
          -  A PASI score of at least 2 (excluding palms and soles) at Baseline.&#xD;
&#xD;
          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as&#xD;
             determined by the Investigator. Stable disease for the past 4 weeks.&#xD;
&#xD;
          -  Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not&#xD;
             including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%.&#xD;
&#xD;
          -  Female subject of childbearing potential (FOCBP) must have a negative serum pregnancy&#xD;
             test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2).&#xD;
             In addition, sexually active FOCBP must agree to use at least one form of highly&#xD;
             effective contraception or a barrier method of contraception throughout the study&#xD;
             according to Contraception Requirements for the protocol.&#xD;
&#xD;
          -  Females of non-childbearing potential must either be premenarchal, post-menopausal&#xD;
             with spontaneous amenorrhea for at least 12 months (post-menopausal status will be&#xD;
             confirmed with FSH testing) or have undergone surgical sterilization according to&#xD;
             Contraception Requirements for the protocol. Prepubescent females must agree to be&#xD;
             abstinent during the study.&#xD;
&#xD;
          -  Subjects in good health as judged by the Investigator, based on medical history,&#xD;
             physical examination, vital signs, serum chemistry labs, hematology values, and&#xD;
             urinalysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who cannot discontinue treatment with therapies for the treatment of&#xD;
             psoriasis vulgaris prior to the Baseline visit and during the study.&#xD;
&#xD;
          -  Planned excessive exposure to treated area(s) to either natural or artificial&#xD;
             sunlight, tanning bed, or other LED.&#xD;
&#xD;
          -  Previous treatment with ARQ-151 or ARQ-154.&#xD;
&#xD;
          -  Females who are pregnant, wishing to become pregnant during the study, or are breast&#xD;
             feeding.&#xD;
&#xD;
          -  Subjects with any serious medical condition or laboratory abnormality that would&#xD;
             prevent study participation or place the subject at significant risk, as determined by&#xD;
             the Investigator.&#xD;
&#xD;
          -  Subjects who are family members of the clinical study site, clinical study staff, or&#xD;
             sponsor, or family members residing in the same household of enrolled subjects.&#xD;
&#xD;
          -  Any condition that in the Investigator's assessment would preclude the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arcutis Study Inquiry</last_name>
    <phone>805.418.5006 Ext. 5</phone>
    <email>studyinquiry@arcutis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 01</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 50</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 45</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 64</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 72</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 21</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 33</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 42</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 57</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 31</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 05</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 65</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 12</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 22</name>
      <address>
        <city>Plainfield</city>
        <state>Illinois</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 10</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 15</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 04</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 02</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 28</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 20</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 14</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 44</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 34</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 63</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 51</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 23</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 25</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 27</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 06</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 13</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 11</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 41</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 54</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 24</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 07</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 17</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 35</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2J 7E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 37</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 47</name>
      <address>
        <city>Winnepeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 43</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 38</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 16</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 29</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 30</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 32</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 71</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 36</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 49</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 09</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

